BioSpace News Archive

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the fourth quarter and full year ended December 31, 2021, after the market close on Thursday, March 10, 2022.

Modulus Discovery, Inc., a preclinical-stage computation-driven drug discovery firm, announces the successful closing of its Series C funding round in the amount of 2.34B JPY.

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference.

Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), in collaboration with MedEd On The Go, today announced the availability of an on-demand, educational symposium entitled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.”

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc.

Yield10 Bioscience, Inc. announced an update on its Camelina line E3902 development program for the purpose of producing low-carbon feedstock oil for the renewable diesel market in the U.S. and Canada.

Influential partners in diabetes, advocacy, and healthcare support effort to combat a nationwide insulin affordability crisis and increase accessibility.

Sera Prognostics Inc. today announced that the company will present at the upcoming virtual 42nd Annual Cowen Health Care Conference and the virtual Oppenheimer 32nd Annual Healthcare Conference.

Zymeworks Inc. today announced that management will participate in upcoming investor conferences during March.

Aruvant Sciences announced management will participate in multiple gene therapy conferences taking place in March.